Navigation Links
CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
Date:2/16/2012

ases that affect fewer than 200,000 people in the U.S. Orphan designation qualifies the sponsor of the product for important tax credits, elimination of FDA license application fees and certain marketing incentives.

CSL Behring's rVIIa-FP was granted Orphan Drug Designations (ODD) by the European Commission in May, 2011.

About Hemophilia
Hemophilia is a congenital bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. In nearly all cases, it affects only males. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective.  Hemophilia B is characterized by deficient or defective factor IX. Hemophilia A affects approximately 1 in 5,000 to 10,000 people. Hemophilia B affects approximately 1 in 25,000 to 50,000 people. The recommended treatment for patients who are factor deficient is to treat by replacement factor therapy. A complication in some patients is the development of inhibitory antibodies (inhibitors) to FVIII or FIX which renders replacement therapy ineffective.  This can occur in up to 25 percent of hemophilia A patients and around 5 percent of hemophilia B patients.  One treatment option for these patients is recombinant activated factor VII (called a bypassing agent) which can be used to achieve hemostasis without the need for factor VIII or IX. 

About the recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
Preclinical studies have confirmed that CSL Behring's rVIIa-FP has favorable pharmacokinetic properties compared with the existing recombinant FVIIa product.
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
2. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
3. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
4. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
5. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
6. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
7. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
8. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
9. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
10. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
11. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Australian drug delivery company, Phosphagenics ... has raised A$19.3 million via a placement of A$16.3 ... , the U.S., Asia and ... a share purchase plan (SPP) to be offered to ... made in two tranches. "This capital raising ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the addition of the "Immunoprotein Diagnostic Testing ... at the highest CAGR of 6% and is ... report to their offering. ... for immunoprotein diagnostic testing has been segmented according ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... 13 Allscripts (Nasdaq: MDRX ... results for the three and nine months ended September ... Monday, November 8, 2010. Allscripts management will host a ... and other information at 4:30 PM Eastern Standard Time ...
... Academy of Managed Care Pharmacy (AMCP) 2010 Educational ... Express Scripts (Nasdaq: ESRX ) will ... driving down healthcare costs and providing increased value ... (Logo:   http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) (Logo:   ...
Cached Medicine Technology:Allscripts to Announce Third Quarter 2010 Results on November 8, 2010 2Allscripts to Announce Third Quarter 2010 Results on November 8, 2010 3Express Scripts Unveils New Opportunities to Drive Down Healthcare Costs; Presents Five Studies at Academy of Managed Care Pharmacy Conference 2Express Scripts Unveils New Opportunities to Drive Down Healthcare Costs; Presents Five Studies at Academy of Managed Care Pharmacy Conference 3
(Date:7/12/2014)... News) -- Burn injuries increase in the summer as people ... experts. Among those most vulnerable to these seasonal fire hazards: ... often get burned by putting their hands on the side ... burn unit at Loyola University Medical Center in Maywood, Ill., ... of ,When you play with fire, you get burned, is ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use ... loss the use of his left side. Eating became a difficult ... help people like them enjoy eating again,” said an inventor, from ... PATRICIA CAROL HALL PLATE (P C H PLATE). , The PATRICIA ... way to eat for individuals who suffer from stroke, experience tremors ...
(Date:7/12/2014)... With prom shopping reaching its final ... is ready to showcase its new and trendy apparels. ... evening dresses in its online shop. Additionally, it is ... these elegant gowns. According to the company’s sales manager, ... 26, 2014. , He says, “Now, worldwide clients ...
(Date:7/12/2014)... Albany, NY (PRWEB) July 12, 2014 ... to 2020 - New and Late-Stage Four-Factor PCCs ... in-depth analysis of the critical care market in ... and Canada. The report provides an estimation of ... to 2020. It covers critical care indications that ...
(Date:7/12/2014)... City, Utah (PRWEB) July 12, 2014 ... two types of startups, with awards being bestowed to ... emphasis spotlighted Utah’s outstanding entrepreneur community with recognition for ... a sustainable model with incoming revenue. , 25 Under ... across the state that are under 5 years old. ...
Breaking Medicine News(10 mins):Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2
... pros, cons to make informed choice about prostate cancer test, ... inability of the prostate specific antigen (PSA) test to distinguish ... a population-wide screening tool, new research claims. , Because of ... overtreatment, according to two reports in the Sept. 25 online ...
... In the future, diagnosing severe personality disorders, evaluating ... analysis of the MAOA genotype may provide more ... according to the Finnish research carried out jointly ... University Central Hospital Psychiatry Centre. "The many ...
... damage more than just your smile? Can failing to attack ... answer to both questions may be yes if you are ... published in the current issue of the Journal of ... Kowolik, B.D.S., Ph.D., professor of periodontics and associate dean for ...
... punishment can affect psychological well-being, , FRIDAY, Sept. 25 (HealthDay ... spanked might lose IQ points. , The good news is ... -- and at least one expert believes that part of ... of favor in the United States and elsewhere. , That,s ...
... ... 1. Practitioner Training: Friday, October 30 , ... Buffalo, NY (PRWEB) September 25, 2009 -- The U.S. Centers ... in the U.S. have an Autism Spectrum Disorder (ASD), which includes autism, Asperger syndrome, ...
... ... Present Completion of New Emergency 911 Center , ... Pittsburgh, PA (PRWEB) September 25, 2009 ... 2009 in San Francisco the firm,s ground-breaking renovation of Washington County,s Emergency 911 ...
Cached Medicine News:Health News:Studies Find PSA Screening Unreliable 2Health News:Studies Find PSA Screening Unreliable 3Health News:New ways to predict violent behavior? 2Health News:Body's immune system response to dental plaque varies by gender and race 2Health News:Spanking May Lower Kids' IQs 2Health News:Spanking May Lower Kids' IQs 3Health News:AutismOne & Autism Canada Present "CHANGING THE COURSE OF AUTISM IN CANADA 2009" University of Toronto 2Health News:AutismOne & Autism Canada Present "CHANGING THE COURSE OF AUTISM IN CANADA 2009" University of Toronto 3Health News:synergIT Presents at VMworld 2009 in San Francisco 2Health News:synergIT Presents at VMworld 2009 in San Francisco 3
For implantation in proximal interphalangeal joints of the lateral toes to correct deformity associated with degenerative or rheumatoid arthritis....
Part of the GraFix® Cruciate Reconstruction System, which is designed to facilitate arthroscopic anterior cruciate ligament reconstructions....
... a new standard in the field of hammertoe ... Made of medical grade silicone, these durable and ... high level of flexibility while maintaining correct toe ... in varying stiffnesses. Lengths are determined by the ...
... Kinetik Great Toe Implant (KGTI) system offers ... of the first MPJ. The implant system ... of motion. , ,The KGTI is the ... metatarsophalangeal joint (MPJ) on the market today. ...
Medicine Products: